- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01413581
Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants (LAIF)
A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Week 32 of Gestational Age
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
The purpose of this study is to demonstrate that rhBSSL improves growth in preterm infants as compared with placebo. The infants should be born before week 32 of gestational age.
The study drug, rhBSSL or placebo, will be administered during a 4 week treatment period by adding it to either infant formula or pasteurized breast milk.
The study will also evaluate the safety and tolerability of rhBSSL.
Eligible patients will be randomized in a ratio of 1:1 (rhBSSL:placebo). The study consists of maximum 1 week screening period, a 4-week treatment period and a 2 year follow-up period.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Bruges, Belgie
- Swedish Orphan Biovitrum Investigational Site
-
Leuven, Belgie
- Swedish Orphan Biovitrum Investigational Site
-
Liege, Belgie
- Swedish Orphan Biovitrum Investigational Site
-
Rocourt, Belgie
- Swedish Orphan Biovitrum Investigational Site
-
Wilrijk, Belgie
- Swedish Orphan Biovitrum Investigational Site
-
-
-
-
-
Amiens, Francie
- Swedish Orphan Biovitrum Investigational Site
-
Lille, Francie
- Swedish Orphan Biovitrum Investigational Site
-
Nancy, Francie
- Swedish Orphan Biovitrum Investigational Site
-
Paris, Francie
- Swedish Orphan Biovitrum Investigational Site
-
Rouen, Francie
- Swedish Orphan Biovitrum Investigational Site
-
Strasbourg, Francie
- Swedish Orphan Biovitrum Investigational Site
-
Toulouse, Francie
- Swedish Orphan Biovitrum Investigational Site
-
-
-
-
-
Ancona, Itálie
- Swedish Orphan Biovitrum Investigational Site
-
Bari, Itálie
- Swedish Orphan Biovitrum Investigational Site
-
Foggia, Itálie
- Swedish Orphan Biovitrum Investigational Site
-
Milano, Itálie
- Swedish Orphan Biovitrum Investigational Site
-
Padova, Itálie
- Swedish Orphan Biovitrum Investigational Site
-
Roma, Itálie
- Swedish Orphan Biovitrum Investigational Site
-
-
-
-
-
Budapest, Maďarsko
- Swedish Orphan Biovitrum Investigational Site
-
Gyula, Maďarsko
- Swedish Orphan Biovitrum Investigational Site
-
Miskolc, Maďarsko
- Swedish Orphan Biovitrum Investigational Site
-
Nyíregyháza, Maďarsko
- Swedish Orphan Biovitrum Investigational Site
-
Pécs, Maďarsko
- Swedish Orphan Biovitrum Investigational Site
-
Veszprem, Maďarsko
- Swedish Orphan Biovitrum Investigational Site
-
-
-
-
-
Berlin, Německo
- Swedish Orphan Biovitrum Investigational Site
-
Freiburg, Německo
- Swedish Orphan Biovitrum Investigational Site
-
Heidelberg, Německo
- Swedish Orphan Biovitrum Investigational Site
-
Wiesbaden, Německo
- Swedish Orphan Biovitrum Investigational Site
-
-
-
-
-
Bydgoszcz, Polsko
- Swedish Orphan Biovitrum Investigational Site
-
Gdansk, Polsko
- Swedish Orphan Biovitrum Investigational Site
-
Lodz, Polsko
- Swedish Orphan Biovitrum Investigational Site
-
Poznan, Polsko
- Swedish Orphan Biovitrum Investigational Site
-
Warszawa, Polsko
- Swedish Orphan Biovitrum Investigational Site
-
-
-
-
-
Ivanovo, Ruská Federace
- Swedish Orphan Biovitrum Investigational Site
-
Nizhniy Novgorod, Ruská Federace
- Swedish Orphan Biovitrum Investigational Site
-
-
-
-
-
Hradec Kralove, Česká republika
- Swedish Orphan Biovitrum Investigational Site
-
Olomouc, Česká republika
- Swedish Orphan Biovitrum Investigational Site
-
Prague, Česká republika
- Swedish Orphan Biovitrum Investigational Site
-
Zlin, Česká republika
- Swedish Orphan Biovitrum Investigational Site
-
-
-
-
-
Almería, Španělsko
- Swedish Orphan Biovitrum Investigational Site
-
Cádiz, Španělsko
- Swedish Orphan Biovitrum Investigational Site
-
Córdoba, Španělsko
- Swedish Orphan Biovitrum Investigational Site
-
Madrid, Španělsko
- Swedish Orphan Biovitrum Investigational Site
-
Málaga, Španělsko
- Swedish Orphan Biovitrum Investigational Site
-
Oviedo, Španělsko
- Swedish Orphan Biovitrum Investigational Site
-
Salamanca, Španělsko
- Swedish Orphan Biovitrum Investigational Site
-
Santiago de Compostela, Španělsko
- Swedish Orphan Biovitrum Investigational Site
-
-
-
-
-
Stockholm, Švédsko
- Swedish Orphan Biovitrum Investigational Site
-
Umeå, Švédsko
- Swedish Orphan Biovitrum Investigational Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Preterm infants born before week 32 of gestation.
- Preterm infant who is less than 33 weeks postmenstrual age at the time of randomization.
- Preterm infant who is appropriate for gestational age (AGA) or small for gestational age (SGA) at birth.
- Preterm infant who is receiving food enterally (bottle or gavage tube) at a level of at least 100 ml/kg/day at randomization.
- Preterm infant whose enteral feeding consists of only infant formula or only pasteurized breast milk at the time of inclusion, and who are expected to remain on only infant formula for 4 weeks, or only pasteurized breast milk for at least 2 weeks following treatment initiation.
- Preterm infant who is expected not to receive any fresh breast milk for 4 weeks following treatment initiation.
- Informed consent is obtained.
Exclusion Criteria:
- Expected stay in the hospital is less than 4 weeks from the first dose of study drug.
- Criteria to ensure no disease or treatment affecting growth or development, e.g. brain disease, necrotizing enterocolitis.
- Enrolled in another concurrent clinical intervention study.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Komparátor placeba: Placebo
|
Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
|
Experimentální: rhBSSL
rhBSSL (recombinant human bile-salt-stimulated lipase)
|
rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Growth velocity in grams per kilogram per day during 4 weeks of treatment.
Časové okno: Baseline and Day 29
|
Baseline and Day 29
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Change from baseline in body weight (g) at 3 months
Časové okno: Baseline and Month 3
|
Baseline and Month 3
|
|
Body weight (g) at 12 months' corrected age
Časové okno: 12 months´ corrected age
|
12 months´ corrected age
|
|
Body weight (g) at 24 months' corrected age
Časové okno: 24 months´ corrected age
|
24 months´ corrected age
|
|
Change from baseline in total body length (mm) at 4 weeks
Časové okno: Baseline and Day 29
|
Baseline and Day 29
|
|
Change from baseline in total body length (mm) at 3 months
Časové okno: Baseline and Month 3
|
Baseline and Month 3
|
|
Total body length (mm) at 12 months' corrected age
Časové okno: 12 months' corrected age
|
12 months' corrected age
|
|
Total body height (cm) at 24 months' corrected age
Časové okno: 24 months' corrected age
|
24 months' corrected age
|
|
Growth restriction
Časové okno: Day 29
|
Defined as growth velocity <15 gram per kilogram bodyweight per day during 4 weeks of treatment
|
Day 29
|
Time to readiness for discharge
Časové okno: Baseline and date of readiness for discharge
|
Time until each of the following are fulfilled
|
Baseline and date of readiness for discharge
|
Time to discharge
Časové okno: Baseline and date of discharge
|
Baseline and date of discharge
|
|
Change from baseline in head circumference (mm) at 4 weeks.
Časové okno: Baseline and Day 29
|
Baseline and Day 29
|
|
Change from baseline in head circumference (mm) at 3 months.
Časové okno: Baseline and Month 3
|
Baseline and Month 3
|
|
Head circumference (mm) at 12 months' corrected age.
Časové okno: 12 months´ corrected age
|
12 months´ corrected age
|
|
Head circumference (mm) at 24 months' corrected age.
Časové okno: 24 months´ corrected age
|
24 months´ corrected age
|
|
Time from baseline to 150 mL/kg/day of enteral feeding
Časové okno: Date of first dose and date 150 mL/kg/day of enteral feeding achieved (or exceeded)
|
Date of first dose and date 150 mL/kg/day of enteral feeding achieved (or exceeded)
|
|
Re-admission to hospital within 1 month of discharge
Časové okno: Date of discharge and date of re-admission
|
Date of discharge and date of re-admission
|
|
Bayley Scale of Infant and Toddler Development, third edition: Cognitive domain composite score 12 months' corrected age
Časové okno: 12 months' corrected age
|
12 months' corrected age
|
|
Bayley Scale of Infant and Toddler Development, third edition: Cognitive domain composite score at 24 months' corrected age
Časové okno: 24 months' corrected age
|
24 months' corrected age
|
|
Bayley Scale of Infant and Toddler Development, third edition: Language domain composite score at 12 months' corrected age
Časové okno: 12 months' corrected age
|
12 months' corrected age
|
|
Bayley Scale of Infant and Toddler Development, third edition: Language domain composite score at 24 months' corrected age
Časové okno: 24 months' corrected age
|
24 months' corrected age
|
|
Bayley Scale of Infant and Toddler Development, third edition: Motor domain composite score at 12 months' corrected age
Časové okno: 12 months' corrected age
|
12 months' corrected age
|
|
Bayley Scale of Infant and Toddler Development, third edition: Motor domain composite score at 24 months' corrected age
Časové okno: 24 months' corrected age
|
24 months' corrected age
|
|
Bayley Scale of Infant and Toddler Development, third edition: Social-emotional domain composite score at 24 months' corrected age
Časové okno: 24 months' corrected age
|
24 months' corrected age
|
|
Bayley Scale of Infant and Toddler Development, third edition: Adaptive behavior domain composite score at 24 months' corrected age
Časové okno: 24 months' corrected age
|
24 months' corrected age
|
|
Neurodevelopment Disability Composite
Časové okno: 24 months' corrected age
|
Presence of :
|
24 months' corrected age
|
Child Behavior Checklist total problem score at 24 months' corrected age
Časové okno: 24 months' corrected age visit
|
24 months' corrected age visit
|
|
Number of patients with at least one treatment emergent Adverse Event
Časové okno: Baseline and Day 29
|
Total and by system organ class and preferred term (coded by MedDRA)
|
Baseline and Day 29
|
Number of patients with at least one treatment emergent Adverse Event
Časové okno: Day 29 and Month 3
|
Total and by system organ class and preferred term (coded by MedDRA)
|
Day 29 and Month 3
|
Number of patients with at least one treatment emergent Serious Adverse Event
Časové okno: Baseline and Day 29
|
Total and by system organ class and preferred term (coded by MedDRA)
|
Baseline and Day 29
|
Number of patients with at least one treatment emergent Serious Adverse Event
Časové okno: Day 29 and Month 3
|
Total and by system organ class and preferred term (coded by MedDRA)
|
Day 29 and Month 3
|
Number of patients with at least one Serious Adverse Drug Reaction
Časové okno: 12 months' corrected age and 24 months' corrected age
|
Total and by system organ class and preferred term (coded by MedDRA)
|
12 months' corrected age and 24 months' corrected age
|
Level of Vitamin A (nmol/L) at 4 weeks
Časové okno: Day 29
|
Day 29
|
|
Level of Vitamin D (nmol/L) at 4 weeks
Časové okno: Day 29
|
Day 29
|
|
Number of outpatient visits from the time of initial hospital discharge to home up to 24 months' corrected age
Časové okno: Date of initial hospital discharge to home to date of 24 months' corrected age
|
Date of initial hospital discharge to home to date of 24 months' corrected age
|
|
Number of inpatient visits from the time of initial hospital discharge to home up to 24 months' corrected age
Časové okno: Date of initial hospital discharge to home to date of 24 months' corrected age
|
Date of initial hospital discharge to home to date of 24 months' corrected age
|
|
Number of days of hospitalization from the time of initial hospital discharge to home up to 24 months' corrected age
Časové okno: Date of initial hospital discharge to home to date of 24 months' corrected age
|
Date of initial hospital discharge to home to date of 24 months' corrected age
|
|
Number of days in intensive care unit from the time of initial hospital discharge to home up to 24 months' corrected age
Časové okno: Date of initial hospital discharge to home to date of 24 months' corrected age
|
Date of initial hospital discharge to home to date of 24 months' corrected age
|
|
Number of days lost from work related to the child's condition from the time of initial hospital discharge to home up to 24 months' corrected age
Časové okno: Date of initial hospital discharge to home to date of 24 months' corrected age
|
Date of initial hospital discharge to home to date of 24 months' corrected age
|
|
Presence of chronic medical conditions/diagnoses at 24 months' corrected age
Časové okno: 24 months' corrected age
|
24 months' corrected age
|
|
Docosahexaenoic acid (% of total fatty acids) in the serum triglyceride fraction at 4 weeks
Časové okno: Day 29
|
Day 29
|
|
Docosahexaenoic acid (% of total fatty acids) in the serum phosphatidylcholine fraction at 4 weeks
Časové okno: Day 29
|
Day 29
|
|
Arachidonic acid (% of total fatty acids) in the serum triglyceride fraction at 4 weeks
Časové okno: Day 29
|
Day 29
|
|
Arachidonic acid (% of total fatty acids) in the serum phosphatidylcholine fraction at 4 weeks
Časové okno: Day 29
|
Day 29
|
|
Number of patients with antibodies to rhBSSL at 4 weeks
Časové okno: Day 29
|
Day 29
|
|
Number of patients with antibodies to rhBSSL at Month 3
Časové okno: Month 3
|
Month 3
|
|
Number of patients with antibodies to rhBSSL at 12 months' corrected age
Časové okno: 12 months' corrected age
|
12 months' corrected age
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Kristina Timdahl, MD, Swedish Orphan Biovitrum
Publikace a užitečné odkazy
Obecné publikace
- Casper C, Carnielli VP, Hascoet JM, Lapillonne A, Maggio L, Timdahl K, Olsson B, Vagero M, Hernell O. rhBSSL improves growth and LCPUFA absorption in preterm infants fed formula or pasteurized breast milk. J Pediatr Gastroenterol Nutr. 2014 Jul;59(1):61-9. doi: 10.1097/MPG.0000000000000365.
- Casper C, Hascoet JM, Ertl T, Gadzinowski JS, Carnielli V, Rigo J, Lapillonne A, Couce ML, Vagero M, Palmgren I, Timdahl K, Hernell O. Recombinant Bile Salt-Stimulated Lipase in Preterm Infant Feeding: A Randomized Phase 3 Study. PLoS One. 2016 May 31;11(5):e0156071. doi: 10.1371/journal.pone.0156071. eCollection 2016.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- BVT.BSSL-030
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .